FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040161091> ?p ?o ?g. }

• W2040161091 endingPage "378" @default.
• W2040161091 startingPage "371" @default.
• W2040161091 abstract "Summary The safety and efficacy of the combination clofarabine/cyclophosphamide/etoposide were evaluated in children with advanced acute lymphoblastic leukaemia (ALL). The study enrolled 25 paediatric patients (median age 12·5 years) with either refractory ( n = 17; 68%) or multiple relapsed ( n = 8; 32%) ALL to receive clofarabine 40 mg/m 2 , cyclophosphamide 400 mg/m 2 and etoposide 150 mg/m 2 , daily for 5 consecutive days. No patient died from treatment‐related complications. The most common adverse events were febrile neutropenia, mucositis and reversible liver toxicity; no case of liver veno‐occlusive disease was reported. The overall remission rate was 56%: 13 patients (52%) achieved complete remission (CR) and one (4%) CR without platelet recovery (CRp). In seven of the 13 (54%) patients achieving CR, remissions were of sufficient duration to allow patients to receive allogeneic haematopoietic stem cell transplantation. The probability of CR/CRp was greater in the 17 patients with B cell precursor ALL than in the eight with T‐ALL (76% vs. 12%, respectively, P < 0·01). The 18‐month overall survival probability was 39% and 0% in patients who did or did not respond to the treatment, respectively ( P < 0·01). These data suggest that the clofarabine/cyclophosphamide/etoposide regimen is well tolerated and can induce clinical response in a relevant proportion of children with refractory/multiple relapsed ALL." @default.
• W2040161091 created "2016-06-24" @default.
• W2040161091 creator A5022712318 @default.
• W2040161091 creator A5032095675 @default.
• W2040161091 creator A5042680923 @default.
• W2040161091 creator A5045580521 @default.
• W2040161091 creator A5047447832 @default.
• W2040161091 creator A5047993250 @default.
• W2040161091 creator A5050682361 @default.
• W2040161091 creator A5057678079 @default.
• W2040161091 creator A5077335202 @default.
• W2040161091 creator A5078844472 @default.
• W2040161091 creator A5081618606 @default.
• W2040161091 date "2009-10-12" @default.
• W2040161091 modified "2023-10-18" @default.
• W2040161091 title "Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia" @default.
• W2040161091 cites W1857665725 @default.
• W2040161091 cites W1919121989 @default.
• W2040161091 cites W1963418965 @default.
• W2040161091 cites W1965658643 @default.
• W2040161091 cites W1966572017 @default.
• W2040161091 cites W1982357299 @default.
• W2040161091 cites W2003437844 @default.
• W2040161091 cites W2010674832 @default.
• W2040161091 cites W2016833582 @default.
• W2040161091 cites W2017265604 @default.
• W2040161091 cites W2024950851 @default.
• W2040161091 cites W2053903261 @default.
• W2040161091 cites W2061585822 @default.
• W2040161091 cites W2074181164 @default.
• W2040161091 cites W2087430096 @default.
• W2040161091 cites W2112174702 @default.
• W2040161091 cites W2116171965 @default.
• W2040161091 cites W2119685895 @default.
• W2040161091 cites W2132243715 @default.
• W2040161091 cites W2133328722 @default.
• W2040161091 cites W2140291353 @default.
• W2040161091 cites W2154267224 @default.
• W2040161091 cites W2156840245 @default.
• W2040161091 cites W2160881482 @default.
• W2040161091 cites W2163334163 @default.
• W2040161091 cites W43502357 @default.
• W2040161091 doi "https://doi.org/10.1111/j.1365-2141.2009.07882.x" @default.
• W2040161091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19747360" @default.
• W2040161091 hasPublicationYear "2009" @default.
• W2040161091 type Work @default.
• W2040161091 sameAs 2040161091 @default.
• W2040161091 citedByCount "76" @default.
• W2040161091 countsByYear W20401610912012 @default.
• W2040161091 countsByYear W20401610912013 @default.
• W2040161091 countsByYear W20401610912014 @default.
• W2040161091 countsByYear W20401610912015 @default.
• W2040161091 countsByYear W20401610912016 @default.
• W2040161091 countsByYear W20401610912017 @default.
• W2040161091 countsByYear W20401610912018 @default.
• W2040161091 countsByYear W20401610912019 @default.
• W2040161091 countsByYear W20401610912020 @default.
• W2040161091 countsByYear W20401610912021 @default.
• W2040161091 countsByYear W20401610912022 @default.
• W2040161091 countsByYear W20401610912023 @default.
• W2040161091 crossrefType "journal-article" @default.
• W2040161091 hasAuthorship W2040161091A5022712318 @default.
• W2040161091 hasAuthorship W2040161091A5032095675 @default.
• W2040161091 hasAuthorship W2040161091A5042680923 @default.
• W2040161091 hasAuthorship W2040161091A5045580521 @default.
• W2040161091 hasAuthorship W2040161091A5047447832 @default.
• W2040161091 hasAuthorship W2040161091A5047993250 @default.
• W2040161091 hasAuthorship W2040161091A5050682361 @default.
• W2040161091 hasAuthorship W2040161091A5057678079 @default.
• W2040161091 hasAuthorship W2040161091A5077335202 @default.
• W2040161091 hasAuthorship W2040161091A5078844472 @default.
• W2040161091 hasAuthorship W2040161091A5081618606 @default.
• W2040161091 hasBestOaLocation W20401610911 @default.
• W2040161091 hasConcept C126322002 @default.
• W2040161091 hasConcept C141071460 @default.
• W2040161091 hasConcept C2776694085 @default.
• W2040161091 hasConcept C2776755627 @default.
• W2040161091 hasConcept C2777063308 @default.
• W2040161091 hasConcept C2777198975 @default.
• W2040161091 hasConcept C2778041864 @default.
• W2040161091 hasConcept C2778119113 @default.
• W2040161091 hasConcept C2778496288 @default.
• W2040161091 hasConcept C2778850193 @default.
• W2040161091 hasConcept C2780775027 @default.
• W2040161091 hasConcept C2781413609 @default.
• W2040161091 hasConcept C2911091166 @default.
• W2040161091 hasConcept C29730261 @default.
• W2040161091 hasConcept C71924100 @default.
• W2040161091 hasConcept C90924648 @default.
• W2040161091 hasConceptScore W2040161091C126322002 @default.
• W2040161091 hasConceptScore W2040161091C141071460 @default.
• W2040161091 hasConceptScore W2040161091C2776694085 @default.
• W2040161091 hasConceptScore W2040161091C2776755627 @default.
• W2040161091 hasConceptScore W2040161091C2777063308 @default.
• W2040161091 hasConceptScore W2040161091C2777198975 @default.
• W2040161091 hasConceptScore W2040161091C2778041864 @default.
• W2040161091 hasConceptScore W2040161091C2778119113 @default.
• W2040161091 hasConceptScore W2040161091C2778496288 @default.

• next